Ayvakit (Avapritinib) Companion Diagnostic Test Enters Priority Review And Approval Process In China
26/07/2021 11:17
July 26 (Reuters) -
* GENETRON HOLDINGS LTD - AYVAKIT (AVAPRITINIB) COMPANION
DIAGNOSTIC TEST ENTERS PRIORITY REVIEW AND APPROVAL PROCESS IN
CHINA
Source text for Eikon: ID:nGNX9dGSV7
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genetron Holdings
See all newsBrief: Genetron Holdings Requested That Trading Of Its ADSs On Nasdaq Be Suspended As Of Close Of Trading On March 28, 2024
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius
U.S. STOCKS ON THE MOVE-Scholar Rock, Target, LL Flooring
U.S. STOCKS ON THE MOVE-First Solar, Genetron, Viasat
Genetron surges on $126 mln deal to go private